Amicus Therapeutics, Inc. (FOLD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Philadelphia, PA, アメリカ. 現CEOは Bradley L. Campbell.
FOLD を有する IPO日 2007-05-31, 499 名の正社員, に上場 NASDAQ Global Market, 時価総額 $4.54B.
Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia that specializes in discovering, developing, and commercializing medicines for rare genetic diseases. The company's lead commercial product is Galafold, an oral precision medicine approved for treating adults with Fabry disease who carry amenable galactosidase alpha gene variants. Its pipeline includes AT-GAA for Pompe disease, AT-GTX-502, a gene therapy in Phase 1/2 development for CLN3 disease, and a gene therapy program targeting CDKL5 deficiency. Amicus maintains strategic collaborations with major research institutions including Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline to advance its development programs. Founded in 2002, the company is focused on addressing significant unmet medical needs in the rare disease community.
